8:36 am ET May 11, 2020
"Moleculin Biotech Inc
(MBRX) and CNS Pharmaceuticals Inc. (CNSP) said Monday they did not
solicit or have any advance knowledge about claims made by third parties
about drug candidate WP1122 and its effect on COVID-19. The two
Houston-based companies had their stocks temporarily halted by the
Securities and Exchange Commission on May 1 over claims and information
in the marketplace about WP1122, (http://www.marketwatch.com/story/sec-takes-action-against-three-more-companies-over-covid-19-claims-2020-05-04
along with the stock of WPD Pharmaceuticals Inc. of Vancouver, British
Columbia. WPD had previously licensed rights to a portfolio of drug
candidates including WP1122 from Moleculin Biotech for certain regions,
while CNS is working with WPD on development. In separate statements,
the companies said those parties made claims and distributed information
about WP1122 during the period stretching from March 20 and May 5
regarding the potential efficacy of the drug in dealing with the
coronavirus that causes COVID-19. "The company neither solicited, had
advance knowledge of, nor played any role in the preparation of such
information, claims or statements," Moleculin said in a statement.
"Moleculin encourages all investors and persons of interest to look at
the Company's releases and filings regarding the potential development
of WP1122 for the treatment of COVID-19." CNS used the same language in
its release. The SEC halt is scheduled to end on May 15."
So, who said what, when and why?